UniProtKB/Swiss-Prot Q15080: Variant p.Arg105Gln

Neutrophil cytosol factor 4
Gene: NCF4
Chromosomal location: 22q13.1
Variant information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Arginine (R) to Glutamine (Q) at position 105 (R105Q, p.Arg105Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CGD3; the protein remains cytosolic, does not localize to phagosomes or endosomes and is unable to bind phosphatidylinositol 3-phosphate (PtdIns(3)P) in a lipid-binding assay; unable to rescue the NADPH-oxidase defect of NCF4 functionally null cells.
Any additional useful information about the variant.



Sequence information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  339
The length of the canonical sequence.

Location on the sequence:   TLPTLPAKVYVGVKQEIAEM  R IPALNAYMKSLLSLPVWVLM
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TLPTLPAKVYVGVKQEIAEMRIPALNAYMKSLLSLPVWVLM

Mouse                         SLPTLPAKVYMGAKQEIAETRIPALNAYMKNLLSLPVCVLM

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 339 Neutrophil cytosol factor 4
Domain 19 – 140 PX
Mutagenesis 92 – 92 K -> A. Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate.
Mutagenesis 94 – 94 Y -> A. Slightly reduces interaction with membranes enriched in phosphatidylinositol 3-phosphate.
Mutagenesis 105 – 105 R -> A. Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate.
Helix 98 – 116


Literature citations

A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity.
Matute J.D.; Arias A.A.; Wright N.A.; Wrobel I.; Waterhouse C.C.; Li X.J.; Marchal C.C.; Stull N.D.; Lewis D.B.; Steele M.; Kellner J.D.; Yu W.; Meroueh S.O.; Nauseef W.M.; Dinauer M.C.;
Blood 114:3309-3315(2009)
Cited for: VARIANT CGD3 GLN-105; CHARACTERIZATION OF VARIANT CGD3 GLN-105;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.